HXBM Stock Overview

Operates as a specialty dermatology and consumer products skin health company in the United States. More details

HXBM fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($2M)

Latest financial reports are more than a year old

Shares are highly illiquid

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Helix BioMedix, Inc. Competitors

Protagenic Therapeutics

NasdaqCM:PTIX

US$1.7m

Theriva Biologics

NYSEAM:TOVX

US$2.6m

Omega Therapeutics

OTCPK:OMGA.Q

US$2.3m

Shuttle Pharmaceuticals Holdings

NasdaqCM:SHPH

US$1.4m

Price History & Performance

Summary of share price highs, lows and changes for Helix BioMedix
Historical stock prices
Current Share Price	US$7.18
52 Week High	US$23.50
52 Week Low	US$7.18
Beta	0
1 Month Change	0%
3 Month Change	-0.14%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	-71.51%
Change since IPO	-98.26%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	HXBM	US Biotechs	US Market
7D	0%	-2.1%	5.1%
1Y	n/a	-18.2%	10.6%

Return vs Industry: Insufficient data to determine how HXBM performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how HXBM performed against the US Market.

Price Volatility

Is HXBM's price volatile compared to industry and market?
HXBM volatility
HXBM Average Weekly Movement	n/a
Biotechs Industry Average Movement	11.9%
Market Average Movement	8.1%
10% most volatile stocks in US Market	16.9%
10% least volatile stocks in US Market	4.2%

Stable Share Price: HXBM's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine HXBM's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1988	n/a	Robin Carmichael	www.helixbiomedix.com

Helix BioMedix, Inc. operates as a specialty dermatology and consumer products skin health company in the United States. It develops and commercializes bioactive peptides, including anti-infective, anti-fungal, and anti-inflammatory peptides for the treatment of skin and wound infections, as well as for the prevention of staphylococcus aureus infections. The company also out-licenses its proprietary peptides to various entities.

Helix BioMedix, Inc. Fundamentals Summary

How do Helix BioMedix's earnings and revenue compare to its market cap?
HXBM fundamental statistics
Market cap	US$1.61m
Earnings (TTM)	-US$2.58m
Revenue (TTM)	US$2.07m

0.0x

P/S Ratio

0.0x

P/E Ratio

Is HXBM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HXBM income statement (TTM)
Revenue	US$2.07m
Cost of Revenue	US$641.22k
Gross Profit	US$1.42m
Other Expenses	US$4.01m
Earnings	-US$2.58m

Last Reported Earnings

Sep 30, 2012

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did HXBM perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/15 02:04
End of Day Share Price	2025/03/05 00:00
Earnings	2012/09/30
Annual Earnings	2011/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Helix BioMedix, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.